Clinical trials
Advanced Lymphoma clinical trials
Below are recruiting advanced lymphoma clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05833893RecruitingPhase 2
Selinexor plus COPL for newly diagnosed advanced NK/T lymphoma
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Beijing, HaidianAges 14 years+ - NCT07209059RecruitingPhase 2
Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
MoscowAges 18–60 - NCT06745076RecruitingPhase 2
Personalized chemotherapy reduction for advanced Hodgkin lymphoma
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
Irvine, CaliforniaAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06755450RecruitingPhase 1
Study of AUR112 for advanced lymphoma or CLL
This trial tests a new oral medication called AUR112 for people with advanced lymphoma or CLL that has not responded to at least 2 prior treatments. The goal is to see if it is safe and how it works in the body.
Vadodara, GujaratAges 18–99 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+ - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT03829254RecruitingPhase 1/Phase 2
NUC-7738 treatment for advanced solid cancers and lymphoma
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
CambridgeAges 18 years+ - NCT07002216RecruitingPhase 2
BrECADD therapy for stage 2B to stage 4 Hodgkin lymphoma
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Miami, FloridaAges 18–60 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05341557RecruitingPhase 1
First-in-human drug study for advanced cancers and lymphoma
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Chaoyang, Beijing MunicipalityAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT06895291Recruiting
Whole body MRI for cancer patients
This study uses whole-body MRI scans to see if they help monitor or diagnose cancer better. It may be an option if your doctor has already recommended this type of scan.
Bologna, BOAges 18 years+ - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT06445517RecruitingPhase 1
ISM8207 for advanced solid tumors and B-cell lymphoma
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT06484985RecruitingPhase 1
Testing AXT-1003 for advanced blood cancers and solid tumors
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT07864701RecruitingPhase 1/Phase 2
Study of an experimental drug for MYC-positive advanced cancers
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06984146RecruitingPhase 2
Nivo40-AVD for advanced Hodgkin lymphoma
This trial tests a combination of nivolumab and chemotherapy (AVD) for people newly diagnosed with advanced classic Hodgkin lymphoma. The goal is to see if adding nivolumab improves treatment outcomes.
MoscowAges 18 years+ - NCT06132503RecruitingPhase 1
Testing LP-284 for advanced lymphomas and solid tumors
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
West Valley City, UtahAges 18 years+ - NCT05949931RecruitingPhase 2
Pianzumab plus AVD for newly diagnosed advanced Hodgkin lymphoma
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advanced Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lymphoma?
- Yes. Clin2 currently lists 72 recruiting advanced lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.